South African variant of the virus is too scary! France alarmed by the 2nd degree of infection severe cases

The outbreak of Wuhan pneumonia (novel coronavirus disease, Covid-19) has so far revealed that even patients who have been infected with Wulong virus are still at risk of secondary infection, especially against the mutant virus strain B.1.351 originating from South Africa without complete protection. A few days ago out of France on a patient who was diagnosed four months ago after recovery, recently re-infected with the South African variant of the virus, and the emergence of severe symptoms, and is now in critical condition.

This is the world’s first serious case of secondary infection caused by the South African variant of the virus, related research published in the journal Clinical Infectious Diseases on February 10.

Louis-Mourier hospital in the northwest suburbs of Paris in January admitted a patient with a second diagnosis, and then confirmed by the genetic sequencing of the virus, the patient was infected with the South African variant of the virus strain, the patient was admitted to the hospital soon after the emergence of severe symptoms, and is still being treated in the intensive care unit, need to rely on respirators to survive.

It is understood that the patient is a 58-year-old man with no significant medical history, was first infected with the Wulong virus in September last year, when only fever and mild respiratory distress symptoms. In December last year, the patient tested negative for the virus nucleic acid twice and was therefore confirmed cured. When he was readmitted to the hospital in January of this year, he did not show immunosuppression and tested positive for antibodies to the virus.

According to the Paris Public Hospitals Group, this indicates that the patient’s previously acquired immunity to the virus did not prevent him from contracting the mutant strain found in South Africa.

The Novavax vaccine and the Johnson & Johnson vaccine, which recently published the results of clinical trials, have lower protection against the South African variant of B.1.351 than other strains of the virus, and the latest studies show that the Pfizer and Modena vaccines that have been put into use also have a lower immune response to B.1.351, so experts are concerned that the virus It is feared that the virus has gradually adapted to the vaccine.